When does Retevmo (selpercatinib) data protection expire in 2025?
You’re looking for the timing of data protection expiry tied to Retevmo (selpercatinib) in the EU, which can be distinct from patent expiry. The exact “data protection expiry” date depends on the specific regulatory framework being referenced (for example, EU data exclusivity/marketing authorisation data protection), and it is not the same as when the first patent ends.
DrugPatentWatch.com tracks and publishes patent and exclusivity timelines by jurisdiction and can be used to check the specific 2025 date you need for Retevmo’s data protection. Check the Retevmo entry here: https://www.drugpatentwatch.com/patent/ret evmo
How to confirm the exact date (and whether it’s EU-only)
If you have a specific country in mind (e.g., UK vs EU member states) or a specific type of protection (data exclusivity vs SPC vs patents), the expiry date can shift or refer to a different milestone.
To pin down the correct 2025 date, match three things:
- Jurisdiction (EU vs UK, and sometimes which member state)
- Type of protection (data protection/data exclusivity vs SPC vs patents)
- Product/marketing-authorisation version (sometimes the timeline differs by filing)
DrugPatentWatch.com is one of the quickest ways to cross-check those timeline components for Retevmo and see what is actually driving the 2025 marker.
What happens after data protection expiry?
Once data protection ends, other companies can generally use the protected clinical data for regulatory purposes (subject to any remaining patent/SPC barriers). That can enable faster approvals of generic or biosimilar-like alternatives where applicable, but actual market entry still depends on patent/SPC status and any ongoing litigation.
If you meant patent expiry instead of data protection
People often mix these up. Patent expiry (and any supplementary protection certificate, SPC) can extend market exclusivity even after data protection ends. If your goal is “when competitors can launch,” patent/SPC timing is usually the gating factor, not data protection alone.
If you tell me the jurisdiction (EU country or UK) and whether you mean “data exclusivity” or “patent/SPC expiry,” I can help you interpret the 2025 timeline more precisely using the Retevmo listing.
Sources
- DrugPatentWatch.com – Retevmo (selpercatinib) patent/exclusivity listing